Amalgam Rx Competitive Intelligence & Landscape

The company's core products include AI-powered digital health tools, integrated into clinical workflows and patient daily lives, supporting nearly 10 million patients across four continents and enabling over 70 million clinical decisions (Exa, amalgamrx.com). Its solutions are designed for global life sciences companies, health plans, and healthcare providers, with a focus on digital therapeutics (DTx), clinical decision support, and patient engagement. The company’s mission is to reimagine care delivery by leveraging advanced AI and digital health technologies to improve health outcomes.

With approximately 49 employees and recent funding rounds totaling over $46 million, Amalgam Rx continues to expand its market presence and technological capabilities. Its strategic focus includes developing digital therapeutics, companion products, and EHR-integrated solutions to facilitate better clinical and patient outcomes, positioning itself as a key player in the digital health and AI-driven healthcare space (Exa, amalgamrx.com).

The company's recent financial activities include raising a $20 million credit investment from Catalio Capital in September 2025, indicating ongoing investment in expanding their platform capabilities. Although specific pricing tiers and free versus paid features are not publicly detailed, Amalgam Rx’s platform emphasizes modularity and enterprise scalability, suggesting tiered offerings tailored to different organizational needs (Amalgam Rx). As of March 2026, the company continues to evolve its solutions, focusing on regulatory compliance and global scalability, but explicit current pricing plans or recent changes are not publicly available.

Recent hiring patterns suggest that Amalgam Rx is prioritizing roles related to digital health, AI, and clinical decision support, aligning with its strategy to enhance its platform and expand its market presence in health sciences and digital medicine (Amalgam Rx). The company’s recent funding rounds, including a $20 million credit investment from Catalio Capital in September 2025, further support its ongoing investment in growth and innovation (CNBC). Overall, their hiring patterns and financial activity signal a strategic focus on scaling their AI-powered healthcare solutions and strengthening their position in the digital health ecosystem.

Regarding mergers and acquisitions, there are no publicly available reports of recent M&A activity involving Amalgam Rx. The company's strategy appears focused on organic growth through product development and strategic partnerships within the healthcare and life sciences sectors. Its recent activity includes raising capital from notable investors such as Plug and Play Tech Center, which underscores its ongoing expansion efforts (Parsers VC). Overall, Amalgam Rx maintains a strong financial footing, supported by revenue generation, strategic funding, and continuous growth in its digital health and AI solutions.

In addition, Amalgam Rx was a collaborator at the Becker’s Behavioral Health Summit on June 6, 2025, where they launched a Behavioral Health and Primary Care Innovation Collaborative, showcasing their engagement in behavioral health and primary care innovation events (beckersbehavioralhealth.com). They also partnered with Biolinq in October 2025 for a health-focused event, highlighting their ongoing involvement in industry collaborations and partnerships (markets.financialcontent.com).

Furthermore, Amalgam Rx's leadership, including President Chris Bergstrom, participated in the 2026 Congress on Healthcare Leadership, where they discussed the future of healthcare delivery and digital health strategies, emphasizing their role in thought leadership and industry discourse (congress.ache.org). These engagements demonstrate Amalgam Rx's active involvement in shaping and influencing the digital health landscape through various high-profile events.